What is HC Wainwright’s Forecast for ACRS FY2027 Earnings?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – HC Wainwright issued their FY2027 earnings estimates for Aclaris Therapeutics in a research report issued to clients and investors on Monday, March 16th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will post earnings of ($0.55) per share for the year. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01). Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%.The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $2.07 million.

A number of other equities analysts also recently weighed in on the stock. Craig Hallum began coverage on shares of Aclaris Therapeutics in a research note on Friday, January 30th. They set a “buy” rating and a $10.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. Finally, Wall Street Zen downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Aclaris Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $9.80.

Aclaris Therapeutics Price Performance

Shares of Aclaris Therapeutics stock opened at $3.88 on Tuesday. The company’s 50 day moving average price is $3.35 and its two-hundred day moving average price is $2.74. The firm has a market capitalization of $467.93 million, a P/E ratio of -7.32 and a beta of 0.88. Aclaris Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $4.89.

Institutional Trading of Aclaris Therapeutics

A number of institutional investors have recently made changes to their positions in ACRS. Millennium Management LLC grew its holdings in shares of Aclaris Therapeutics by 111.0% during the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock worth $6,325,000 after acquiring an additional 2,175,101 shares during the period. Geode Capital Management LLC increased its holdings in Aclaris Therapeutics by 108.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock worth $3,501,000 after buying an additional 1,282,042 shares in the last quarter. Kotler Kevin purchased a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at about $5,135,000. Palo Alto Investors LP lifted its holdings in shares of Aclaris Therapeutics by 12.7% during the 3rd quarter. Palo Alto Investors LP now owns 1,566,840 shares of the biotechnology company’s stock valued at $2,977,000 after buying an additional 176,812 shares during the period. Finally, State Street Corp lifted its holdings in Aclaris Therapeutics by 35.3% in the fourth quarter. State Street Corp now owns 1,506,403 shares of the biotechnology company’s stock valued at $4,534,000 after acquiring an additional 393,257 shares during the period. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.